Michigan Medicine details treatment-access concerns as 7-OH policy shifts

Why it matters

The article connects changing availability of synthetic kratom-related products with a practical treatment question: whether people who develop dependence can access care. It points patients and clinicians toward substance-use treatment and emergency-response resources.

The big picture

Federal action effective August 26 temporarily placed mitragynine pseudoindoxyl, MGM-15 and MGM-16 in Schedule I. The article says 7-OH itself was not federally scheduled at the time of publication, although the DEA had reopened comments on a proposed threshold-based action. It distinguishes these products from natural leaf kratom while describing state and local restrictions that vary across the country.

Key findings

• Michigan Medicine reports that the federal order applies to mitragynine pseudoindoxyl, MGM-15 and MGM-16 from August 26, 2026
• The article says products containing 7-OH but none of those three compounds could still technically be sold where state law allowed at publication
• A Michigan House bill to ban 7-OH and kratom products had passed the House but had not been taken up by the state Senate
• Clinician Eliza Hutchinson reported that some patients contacted her clinic after hearing products might leave retail shelves
• The article identifies buprenorphine, naloxone and emergency care as relevant elements of clinical response to opioid-like effects and substance-use concerns

What they say

Eliza Hutchinson, M.D., said: “Regardless of the outcome of the DEA scheduling decision, the need for treatment access and education is increasing.”

Bottom line

Policy changes may alter product availability quickly, so treatment access and accurate clinical information remain central for people affected by 7-OH or related synthetic opioids.